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Background: The prevalence of depression in young people is increasing. The predominant co-morbidities of
juvenile depression include sleep disturbances and persistent problems with the sleep-wake rhythm, which have
shown to influence treatment outcomes negatively. Severe mood dysregulation is another condition that includes
depressive symptoms and problems with the sleep-wake rhythm. Patients with severe mood dysregulation show
symptoms of depression, reduced need for sleep, and disturbances in circadian functioning which negatively affect
both disorder-specific symptoms and daytime functioning. One approach to treating both depression and
problems with the sleep-wake rhythm is the use of light therapy. Light therapy is now a standard therapy for
ameliorating symptoms of seasonal affective disorder and depression in adults, but has not yet been investigated in
children and adolescents. In this trial, the effects of 2 weeks of morning bright-light therapy on juvenile depression
and severe mood dysregulation will be evaluated.
Methods/design: A total of 60 patients with depression, aged between 12 and 18 years, in some cases presenting
additional symptoms of affective dysregulation, will be included in this trial. Morning bright-light therapy will be
implemented for 2 weeks (10 sessions of 45 minutes each), either with ‘active’ light (10,000 lux) or ‘inactive’ light
(100 lux). A comprehensive test battery will be conducted before and after treatment and at follow-up 3 weeks
later, to assess depression severity, sleep, and attention parameters. Melatonin levels will be measured by assessing
the Dim Light Melatonin Onset.
Discussion: In this pilot study, the use of morning bright-light therapy for juvenile depression and severe mood
dysregulation shall be evaluated and discussed.
Trials registration: Current Controlled Trials ISRCTN89305231
Keywords: Bright-light therapy, Depression, Adolescents, Sleep disturbances, Severe mood dysregulationBackground
Major depressive disorder (MDD) is one of the most
prominent health problems affecting mood as well as
mental and physical conditions. About 1 out of 10 adults
experiences affective disturbances and a loss of interest,
the core symptoms of depression [1]. Behavioral and cog-
nitive difficulties, including memory or attention prob-
lems, changes in eating behavior, and persistent sleep* Correspondence: sarah.bogen@wkp-lwl.org
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reproduction in any medium, provided the ordisturbances, have been reported [2-4]. Effective treatment
strategies for MDD in adults include antidepressant
medication, psychotherapy, or a combination of both [5].
In adolescents, prevalence rates for MDD, also called ju-
venile depression in this group, are about 4 to 8%, and the
rate seems to be increasing [6]. This relatively high rate is
of particular interest for two reasons.
First, the presentation of MDD in young people might
be different from that in adults. However, there are
many symptoms common to both groups, including
irritability, low frustration tolerance, violent temper, and
externalizing and histrionic behavior [7]. TheseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sequences, including impaired academic and occupa-
tional functioning, high-risk sexual activity, and social
difficulties [8]. Moreover, the predominant symptoms of
juvenile depression implicate sleep disturbances and per-
sistent problems with the sleep-wake rhythm [9,10],
which are present in about 75% of adolescents with de-
pression [11].
Second, treating juvenile depression is difficult. The
available treatments have substantial shortcomings, and
remission rates of moderate to severe depression are low
[12,13]. Although cognitive behavioral therapy (CBT) is
the treatment of choice for mild depression, CBT alone
might not be sufficient in more severe cases. Several ran-
domized controlled trials (RCTs) have indicated no or
only small differences between pharmacotherapy with a
selective serotonin reuptake inhibitor (SSRI), psycho-
therapy, and placebo (for an overview, see the American
Academy of Child and Adolescent Psychiatry website
[14]). Combination trials of both SSRIs and psychothe-
rapy, a treatment that is commonly implemented in
clinical practice, have not shown superiority to treat-
ment with either therapy alone, and remission rates have
been reported to be less than 40% [14,15]. Another im-
portant point is that treatment research has primarily
focused on acute treatment, whereas early-onset depres-
sion is often chronic and recurrent. One influencing
factor might be the presence of co-occurring sleep dis-
turbances, which often remain as a residual symptom
even after successful acute treatment [13]. These prob-
lems with the sleep-wake rhythm have been suggested to
be a robust risk factor for the development of both the
first depressive episode and recurrent episodes [1]. Sleep
disturbances and insomnia presenting in juvenile depres-
sion are associated with higher depression severity,
greater fatigue, and higher rates of suicidal behavior
[16]. Emslie et al. noted in two large, double-blind RCTs
[17] that sleep disturbances may negatively affect treat-
ment response, as adolescents receiving treatment with
the SSRI fluoxetine were less likely to respond to the treat-
ment if they also had sleep disturbances. Based on these
results, it is essential that sleep disturbances are adequately
assessed and co-treated consistently along with the depres-
sion. However, there is as yet no evidence-based treatment
for insomnia in adolescents with depression [17].
One possible non-pharmacological treatment approach
for ameliorating depressive symptoms and co-occurring
sleep disturbances is morning bright-light therapy, which
has been used successfully for adults [18,19]. Light therapy
has primarily been studied in patients with seasonal
affective disorder (SAD) and has been shown to have good
efficacy in ameliorating depressive symptoms in this sub-
group. In adults with SAD, Lam et al. [20] reported that
light therapy was as efficient as antidepressant treatmentwith fluoxetine, but had a faster onset of action and fewer
side effects. The effects of light therapy are apparent after
about 1 week of treatment [21], and remission rates of up
to 80% have been reported for SAD [22]. In addition, Even
and colleagues [19] carried out a systematic review based
on 15 studies, and reported efficacy of light therapy as an
adjuvant treatment to antidepressants in non-seasonal
depression as well. However, they concluded that the
evidence for the effects of light therapy alone (without
antidepressant) was still inconsistent [19].
Light therapy has also been shown to be effective for
other symptoms besides depression. For example, it may
induce stabilization of the circadian rhythm (the bio-
logical rhythm controlling the sleep-wake cycle) and
thereby, improve difficulties with sleep onset and diffi-
culties sleeping through the night [23]. This is of par-
ticular interest because an intimate relationship between
sleep and emotion regulation has been reported [24],
with the consequences of disturbed sleep including
symptoms such as heightened impulsivity and aggressive
behavior. Preliminary evidence indicates that light ther-
apy has a positive influence on behavior, irritability and
attention parameters [25-27]. Furthermore, it has been
suggested that, independent of specific diagnoses, the
severity of psychiatric symptoms increases and long-
term outcomes worsen when circadian disturbances are
present [28], reinforcing the crucial relationship between
sleep and regulation of emotions. Therefore, it is reason-
able to assume that light therapy might be a useful
method of stabilizing circadian functioning and thereby
inducing more general improvements on emotional
regulation. Despite these positive results in adults, there
have only been very few studies investigating light ther-
apy for adolescents. One RCT of children and adoles-
cents with SAD showed that 1 week of light therapy
significantly decreased parent-rated depressive symp-
toms [29]. A more recent 1-week trial of light therapy as
an adjunctive treatment for young people with mild de-
pression showed significant improvements in depression
scores on the Beck Depression Inventory (BDI) from
baseline to the end of therapy in the active treatment
group [30]; however, participants received concomitant
CBT and pharmacotherapy during the trial, which may
have led to additional positive effects.
One phenotype that has a high prevalence rate in
clinical populations and that elicits considerable pro-
blems with emotional regulation, depression, and cir-
cadian disturbances is severe mood dysregulation
(SMD). Children and adolescents with SMD show se-
vere affective and behavioral dysregulation, including
irritable mood, hyperarousal, and increased reactivity
to negative emotional stimuli [31,32]. Characteristics
of SMD include not only depressive symptoms that
might develop into MDD later on [33], but also
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disturbances in sleep continuity at sleep onset and
through the night, lower sleep efficiency, reduced
rapid eye-movement (REM) sleep and impaired day-
time behavior, which have consistently been reported
[34-36]. The initial treatment approaches, similar to
those for pediatric bipolar disorder and attention
deficit hyperactivity disorder (ADHD), include mood
stabilizers and stimulants, and have shown some posi-
tive effects [37,38]. A novel psychosocial treatment with
CBT indicated improvements in depressive symptoms,
mood lability, and global functioning [39]. Although these
initial treatment approaches were reported to have some
positive effects on SMD symptoms, children and adoles-
cents with SMD and additional ADHD were more likely
to remain significantly impaired than those with only
ADHD after a 3-week combination trial with stimulants
and behavior modification therapy [37]. Therefore, a wider
range of treatment approaches for SMD is needed, as
those that have been evaluated to date have shown only
limited improvements. It is possible that, as in juvenile de-
pression, circadian disturbances might be an influencing
factor on treatment outcome in SMD. Considering that
preliminary results of light application besides SAD and
MDD have shown positive influences on affective and be-
havioral regulation and on circadian functioning, light
therapy might constitute a reasonable co-treatment for
SMD symptoms as well [40].
The proposed study is an RCT of bright-light ther-
apy in juvenile depression. We plan to enroll 60 ado-
lescents with depression. We hypothesize that 2 weeks
of morning bright-light therapy will improve depres-
sive symptoms and additional sleep disturbances in
these adolescents. On an exploratory basis, the study
will additionally evaluate the outcomes of morning
light therapy on SMD symptoms.Table 1 Eligibility criteria
Inclusion criteria Moderate to severe depression (ICD
Being 12 to 18 years of age
Ability to understand character and
Written informed consent of the per
Exclusion criteria Acute suicidal tendencies
Treatment with antidepressants
Treatment with beta-blockers
Treatment with high-potency neuro
Diagnosis of bipolar 1 disorder or sc
Diseases of the eye with involvemen
Pregnancy or lactation
BDI-II, Beck Depression Inventory, second edition; ICD-10, International ClassificationMethods/design
Participants and recruitment
Participants of this study will be recruited from the
inpatient unit of the LWL (University Hospital Hamm,
Ruhr University Bochum, Germany), a tertiary-care
hospital for child and adolescent psychiatry. The
hospital provides child psychiatric care for a popula-
tion of 1.6 million inhabitants, covering both urban
and rural areas, and is the sole provider of inpatient
care serving the study area.
All patients between 12 and 18 years who are re-
ferred to the hospital will be screened consecutively
for participation. Patients with moderate or severe de-
pression (according to the International Classification
of Diseases, version 10; (ICD-10), based on parent and
child interviews and assessed using the second edition
of the BDI (BDI-II [41]), will be included in the trial.
Diagnoses will be confirmed using the Diagnostic
Checklist for Depressive Disorders [42] conducted by
a clinical psychologist or child psychiatrist. Presence
of co-morbid disorders will be allowed, excluding bi-
polar 1 disorder and schizophrenia. The specific eligi-
bility criteria of the study are listed in Table 1.
Ethics and written consent
The study has been approved by the medical ethics com-
mittee of the Ruhr-University Bochum, Germany (regis-
tration number 3996–11), and will be conducted in
accordance with the Helsinki Declaration. Before enter-
ing the study patients will be informed about the study
objectives, study design, and potential risks by one of
the main investigators and will also receive this informa-
tion in writing. Patients will be informed about their
right to withdraw from the study at any time. Written
consent will be obtained from the persons in charge with
primary custody. After informed consent is obtained, the-10/BDI-II)
individual consequences of the trial
son with primary custody must be available before enrolment in the trial
leptic drugs
hizophrenia
t of the retina
of Diseases, version 10.
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patient entering the study.
Randomization and blinding
After screening, patients will be randomized and allocated
to either the active light intervention (experimental group;
10,000 lux) or to the inactive light intervention (control
group; 100 lux). Randomization will be carried out by ran-
domly drawing group allocations by hand from a rando-
mizer box in which the number of possible group
allocations is equal. For practical reasons, the primary in-
vestigator of the study who is performing the rando-
mization and delivering the treatments (but is not
involved in outcome ratings) will be aware of the partici-
pants´ allocation, but all therapists on the patients´ units
will be blinded to the allocation groups.
Interventions
Interventions will be conducted following the protocols
described by Wirz-Justice et al. [43]). Based on empirical
evidence indicating good results for light therapy with a
duration of 7 to 14 days for non-seasonal depression
[18,19], two parallel interventions will be created, each
lasting 2 weeks, and will be conducted in the mornings,
in addition to usual treatment in the respective treat-
ment units.
Experimental group
Patients randomly allocated to the experimental group will
receive 2 weeks of active morning light therapy with
10,000 lux at eye level in gaze direction (LD 110®;
DAVITA® Medizinische Produkte GmbH & Co. KG, Kleve,
Germany), with each session lasting for 45 minutes. The
therapy will start about 7.5 hours after the estimated
individual dim light melatonin onset (DLMO), estimated
by the Morningness-Eveningness-Questionnaire (MEQ)
[44]), as it has been shown that by administering light at
that time point, the efficacy of light therapy is increased
[22].
Control group
A valid placebo group will be created by randomly
assigning half of the patients to the control group to re-
ceive 2 weeks of inactive light therapy not exceeding 100
lux at eye level in gaze direction (Luxor LED light alarm
clock, lowest level; DAVITA® Medizinische Produkte
GmbH & Co. KG, Kleve, Germany), with each session
lasting for 45 minutes. Each session will commence about
7.5 h after the estimated DLMO to parallel the experimen-
tal group.
Finding an appropriate control group for light therapy
to minimize placebo effects is difficult, because these ef-
fects are expected to be relatively high [19,45,46]. To de-
sign conditions that the patients will not consider acontrol group, we have chosen professional light-therapy
devices for both groups, adjusting the lux levels respect-
ively. To control for possible expectation bias, both
groups will be instructed that the aim of the study is to
compare two different types of light therapy. Moreover,
to minimize bias, the therapists on the respective units
will be informed that the light therapy for both groups is
active.
To ensure that an appropriate and constant number of
lux is administered in each group, intensities will be quan-
tified using a lux meter (PCE-172; PCE Instruments,
Meschede, Germany). The light intensity that will be used
in this study lies within the range of normal daylight
exposure. Its long-term ocular safety has been shown in
patients with SAD who received bright-light therapy at an
illuminance level of 10,000 lux [47].
During the interventions, patients will be allowed to
have breakfast or read magazines and books with neutral
content (for example, magazines containing plain infor-
mation without emotionally arousing material). To ensure
that every participant has received the same amount of
light therapy at the end of the treatment period, treatment
can be prolonged for up to 1 day if a patient misses a
light-therapy session for some reason (for example,
somatic illness). If a patient misses more than two ses-
sions, he/she will be excluded from the study. In total,
about three patients can be treated in parallel within each
group (see Figure 1 for a flow chart of the study).
Primary and secondary endpoints
The primary endpoint of the study is the change in de-
pression symptoms (BDI-II total score) during the trial.
Secondary endpoints include changes in general psycho-
pathology, sleep, circadian functioning (including mela-
tonin assessment), affective dysregulation, behavior, and
attention parameters. All questionnaires will be pre-
sented in German, and will be completed within the
hospital.
Assessments
BDI-II BDI-II is a measure of the severity of depressive
symptoms and has been used widely in treatment studies
for juvenile depression [41]. It can be used to directly
compare effect sizes between different kinds of interven-
tions. The German version has shown good psychomet-
ric properties, with good test-retest-reliability (r ≥ 0.75)
in a non-clinical population, and good internal con-
sistency (α coefficient = 0.92) for adolescent inpatients
with depression [48,49].
Clinical global impression scale Assessment of general
psychopathology will be performed using the Clinical
Global Impression Scale (CGI) for estimating symptom
severity (CGI-S) and improvement (CGI-I) [50,51]. The
Allocated to “inactive” light therapy (N=..)
Received allocated intervention (N=..)




Lost to follow-up (N=..)
Discontinued intervention (N=..)
Excluded (N=..)




Assessed for eligibility (N=..)
Allocated to “active” light therapy (N=..)
Received allocated intervention (N=..)




Lost to follow-up (N=..)
Discontinued intervention (N=..)
Figure 1 Study flow chart.
Bogen et al. Trials 2013, 14:178 Page 5 of 11
http://www.trialsjournal.com/content/14/1/178CGI is a 7-point scale that requires a rating of illness se-
verity at the time of assessment. Because severity esti-
mation in the CGI is performed in relation to other
patients, it is a subjective assessment tool. In the pro-
posed study, rating will be performed by clinicians
blinded to group allocation.
Sleep questionnaire B - revised Sleep and sleep diffi-
culties will be assessed by using the Sleep Questionnaire
(Schlaffragebogen) B - Revised (SF B/R) described by
Görtelmeyer et al. [52]. This questionnaire contains 31
questions, assessing the 2 weeks prior to assessment.
Completion takes about 5 to 10 minutes, and 11 sleep in-
dices can be created including: difficulties in sleep onset
and in sleeping through the night, premature awakening,
general sleep characteristics, total sleep duration, and
sleep factors consisting of sleep quality, feeling of recovery
after sleeping, mental balance before going to sleep,
feeling of mental exhaustion before going to sleep, and
psychosomatic symptoms during sleep phase. Internal
consistency is moderate to excellent (α coefficient = 0.68
to 0.92) for clinical populations. Test-retest reliability indi-
cates that relatively stable sleep-related behavior and expe-
riences can be assessed (r = 0.53 to r = 0.91).
DLMO Melatonin production by the pineal gland is
under the influence of the suprachiasmatic nucleus of
the hypothalamus (SCN), which receives informationfrom the retina about daily patterns of light and dark-
ness [53]. Production of melatonin is inhibited by light
and induced by darkness. Hence, when dim lighting is
provided, the human body starts producing melatonin
about 2 hours before bedtime, and this physiological
process is called DLMO. Assessment of the DLMO can
be considered the gold standard for measuring mela-
tonin levels and circadian rhythms. In the present study,
at the assessments T1, T2, and T5, four sequential mela-
tonin saliva samples will be collected at hourly intervals,
respectively. Collection starts from 4 hours before pre-
dicted bedtime (19.00 to 22.00 hours) under conditions
of dim light. Light therapy has been shown to be most
effective when it is applied about 7.5 to 9.5 hours after
the individual DLMO [22].
Saliva will be sampled using sterile collection devices
(Salivettes; Sarstedt AG & Co, Nümbrecht, Germany).
On the day of sampling, patients will be instructed to
avoid caffeinated beverages, orange juice, eggs, cho-
colate, and bananas, because all these have been shown
to have a possible influence on melatonin level. During
the evening, electronic devies such as video games, TV,
and cell phones will not be allowed because the light
produced by such devices may have a melatonin-
suppressing effect [54]. Patients will be instructed to
refrain from food or drinks for 30 minutes before sam-
pling, and directly before sampling they will be
instructed to rinse their mouth with water. Samples will
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analyzed simultaneously. This will be performed in a
specified laboratory in which melatonin concentrations
will be determined, and the individual DLMO will be
calculated.
Morningness-eveningness questionnaire For estima-
ting circadian preferences independent of physiological
parameters, the German version of the Morningness-
Eveningness Questionnaire (MEQ) will be used [44,55].
With this questionnaire, the individual chronotype can
be estimated based upon 19 questions that are summed
to give a total score and the individual DLMO is then
estimated, as it has been shown to have a good correl-
ation with the MEQ [56]. Using this procedure, the opti-
mal time point for light exposure can be estimated
directly (about 7.5 h after the individual DLMO) without
the requirement for physiological data.
Child behavior checklist The Child Behavior Checklist
(CBCL) is one of the best-studied, empirically derived
parent checklists for measuring general child and adoles-
cent psychopathology [57]. It assesses the child’s beha-
vior over the past 6 months using a total of 118 items
(plus two optional questions), and is rated by the parents
or primary caregivers. The questionnaire includes a total
problem score, two higher level scales (externalizing
problems and internalizing problems), and eight syn-
drome scales (withdrawn, somatic complaints, anxious/
depressed, social problems, thought problems, attention
problems, delinquent behavior, and aggressive behavior).
The reliability, factorial validity and discriminant validity
of the German adaptation of the CBCL have been con-
firmed by previous studies [58,59]. Recently, a specific
‘dysregulation profile’ has been identified in the CBCL,
capturing severe affective dysregulation (CBCL-DP) [60].
This profile is characterized by simultaneous high values
on the syndrome scales ‘anxious/depressed,’ ‘attention
problems,’ and aggressive ‘behavior.’ The CBCL-DP has
been consistently found to be associated with disruptive
behavior disorders, suicidal behavior, and reduced need
for sleep [61-64], and it will be calculated to assess the
phenotype of affective dysregulation.
Strengths and difficulties questionnaire In addition
to the CBCL, the Strengths and Difficulties Question-
naire (SDQ) will be used in order to assess short-term
changes and to evaluate parent and patient ratings.
The SDQ is a brief behavioral screening questionnaire
assessing 25 attributes, some positive and others nega-
tive, which can be allocated to five scales (emotional
symptoms, conduct problems, hyperactivity/inatten-
tion, peer relationship problems, and pro-social beha-
vior) [65]. These scales can be summed to calculate atotal difficulties score and, like in the CBCL, a dys-
regulation profile can be calculated that corresponds
to the CBCL-DP, with the advantage of being able to
assess short-term changes [66]. In this study, patient
and parent rating versions of the SDQ will be used.
The sensitivity to change of the SDQ allows estimation of
treatment efficacy (α = 0.73; retest stability = 0.62) [67],
therebv allowing monitoring of symptom changes of
affective dysregulation and behavior during the trial.
Tests of attentional performance With the Tests of
Attentional Performance (TAP), a large spectrum of spe-
cific attentional performances can be assessed in a
computerized form [68]. The following four subtests will
be administered to evaluate highly relevant attention-
related parameters.
1) Covert shift of attention. This assesses the ability to
shift the attentional focus, measuring reaction times
for valid and invalid cues in a visual reaction time
task.
2) Go/nogo. Assesses the ability to suppress a response
in the presence of irrelevant stimuli.
3) Alertness. Assesses the general level of arousal (tonic
arousal), its stability over a longer period (intrinsic
arousal) and the magnitude of elevation of arousal,
induced by a warning signal (phasic arousal).
4) Divided Attention. Assesses the ability to divide
attention to auditory and visually presented target
stimuli.
Internal consistency for all these subtests lies between
0.60 and 0.83 [68].
Seasonal pattern assessment questionnaire The Sea-
sonal Pattern Assessment Questionnaire (SPAQ) is a
questionnaire for retrospectively assessing change in
mood and vegetative functions with the seasons [69]. It
is a frequently used screening instrument for assessing
symptoms of SAD, with a high internal consistency [70]
and has recently been used in young adults [71]. In the
present study it will be administered to calculate a total
seasonality score, with seasonality being the degree to
which seasonal changes affect criteria such as mood,
energy, sleep length, appetite, food preference, or the
wish to socialize with other people [69], and thus will be
used to control for seasonal effects.
Therapy expectancy Therapy expectancy will be as-
sessed by using a modification of the Credibility/
Expectancy Questionnaire, which is a quick and easily
administered scale for measuring treatment expectancy
and rationale credibility for use in clinical outcome stu-
dies [72]. High internal consistency has been reported,
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item correlations between studies ranged from 0.53 to
0.85 for the items on the expectancy factor, and
between 0.62 and 0.78 for items on the credibility fac-
tor. Test-retest reliability over a 1-week period was
also found to be good, at 0.82 for expectancy and 0.75
for credibility [72]. In the proposed study, the ques-
tionnaire will be used to control for placebo effects,
which are expected to be relatively high for light-
therapy studies.
Culture fair intelligence test 20 – revised The Culture
Fair Intelligence Test 20 – Revised (CFT20-R) is an
economic, computerized general intelligence screening
test assessing ‘general fluid ability’ [73], that is, the
ability to solve formal logic tasks with varying com-
plexity within a specific time frame. The CFT20-R
uses language-free tasks and is therefore also appro-
priate for people with language deficiencies. It is stan-
dardized for children and adults (8.5 years of age and
above) and has high test-retest coefficients (r = 0.80
to 0.83, uncorrected) and high internal consistency
(α = 0.95).Adverse events At each assessment, the participants
will be asked to report any adverse events (AEs).
Reported AEs of light therapy side effects include jumpi-
ness, jitteriness, headache, or nausea (for an overview,
see Terman et al. [22]). AEs will be assessed by using
open questions, asking about general AEs and their se-
verity during the study period.
Time points of assessments
The assessment time points are as follows.
 T1: The initial assessment for eligible patients will
be carried out after about 1 week of care in the unit.
At this point, patients will have become used to
being in the hospital, and will probably have a more
regular day and night rhythm.
 T2: After 2 weeks of morning light-therapy
intervention, there will be a comprehensive post-
therapy assessment.
 T3: One week later, depression severity will be
assessed to monitor changes.
 T4: Another week later, there will be another
assessment of depression severity.
 T5: Three weeks after the light-therapy
interventions have ended, another comprehensive
assessment will be carried out.
An overview of the timeline of the study is shown in
Figure 2.Data analysis
Sample-size calculation
Estimates of a clinically relevant effect size were derived
from a meta-analysis that evaluated effects of bright-
light therapy for seasonal and non-seasonal depression
in adult outpatients [74]. A similar study for adolescent
inpatients is not available. Therefore, effect-size calcula-
tion will be based on evidence from adult outpatients.
Although research is generally scarce, it is assumed that
the active light therapy intervention for SAD will have
an effect size (pre-post) of about 0.78 [75], which can be
considered a conservative estimate because effect sizes
might be considerably higher [74]. Golden et al. [74] di-
vided the studies used in their meta-analysis into four
categories, and derived effect sizes for them. In the
category ‘non-seasonal depression’, an effect size of 0.53
was reported for bright-light treatment, with a 95% con-
fidence interval of 0.18 to 0.89. Conservative calculations
indicate that the expected outcome for our study will
require a total sample size of 54 subjects (α = 0.05, two-
sided test) to achieve a power of 80%.
Statistical analyses
Data will be assessed using SPSS software (version 20;
SPSS Inc., Chicago, IL, USA). Correctness of the data
will be assured by double-entry of the data. Data will be
analyzed according to both intention-to-treat (ITT) and
per-protocol (PP; efficacy population) principles. ITT
will assess all randomized patients, while PP analyses
will assess patients who receive 2 weeks of morning light
therapy with no violation of the study protocol.
All planned comparisons will compare T2 to T5 rela-
tive to T1. The primary endpoint of the study is change
in depressive symptoms (BDI-II total score) during the
trial. Baseline depression level (that is, BDI-II total score
at T1) will be controlled for in the two-factor repeated-
measures ANCOVA. This model accounts for diffe-
rences between groups at baseline. Furthermore, the
study will evaluate whether the effects of morning light
therapy on mood might partly be mediated by its effect
on the circadian rhythm, and will be assessed by ques-
tionnaires and saliva samples. For missing values, the
multiple imputations (MI) technique will be used, be-
cause a recent meta-analysis for RCTs in obesity found
this to have modest superiority to fitting mixed linear
models or using last observation carried forward (LOCF)
methods [76]. With the MI technique, plausible values
for the missing data are imputed. Each of the datasets is
then analyzed separately using the desired model (in this
case, the two-factor repeated-measures ANCOVA). With
this parameter, estimates are made for each of the
datasets, and these are then combined using standard
rules for MI analyses [77,78]. These combined parameter
estimates can then be used for hypothesis testing and for
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Figure 2 (See legend on next page.)
Bogen et al. Trials 2013, 14:178 Page 8 of 11
http://www.trialsjournal.com/content/14/1/178
(See figure on previous page.)
Figure 2 Time schedule for the pilot study. BDI-II, Beck Depression Inventory-II; CFT 20-R, Culture Fair Intelligence Test – Revised, CGI-S/ I,
Clinical Global Impression Scale-Severity/ Improvement; DLMO, Dim Light Melatonin Onset; MEQ, Morningness-Eveningness-Questionnaire; SDQ,
Strengths and Difficulties Questionnaire; SF B/R, Sleep Questionnaire B - Revised; SPAQ, Seasonal Pattern Assessment Questionnaire; TAP, Tests of
Attentional Performance.
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measures ANCOVA will be used with group as
between-subject factor and time as within-subject fac-
tor (T1 to T5). In cases of significant correlations with
the primary endpoint, covariates will include baseline
BDI-II score, gender, intelligence, seasonality, and cir-
cadian preference. The 95% confidence intervals and
pre-post effect sizes will be derived for each analysis.
All tests of statistical significance will be interpreted
with a criterion of P < 0.05, two-sided.Discussion
We have presented a design and protocol for an RCT of
light therapy for juvenile depression and severe affective
and behavioral dysregulation in a naturalistic tertiary-care
inpatient setting. This initial pilot study will evaluate the
feasibility and acceptance of this chronobiological interven-
tion for depressive adolescents by implementing a 2-week
period of bright-light therapy. Because it will be imple-
mented in an inpatient setting, there are several limita-
tions, such as the short duration of bright-light therapy,
interruption by weekend breaks, and lack of daily mood
self-assessments that would allow a detailed picture of res-
ponse to this chronobiological intervention. An additional
challenge is the issue of blinding. In their systematic re-
view, Even et al. [19] discussed the possibility that some
patients in a control group exposed to a device that only
delivers 100 lux may correctly guess that they have been al-
located to the placebo group. To control for possible ex-
pectation bias, both groups in this study will be instructed
that the aim of the study is to compare two different types
of light therapy. In accordance with this, it is important to
bear in mind that even 100 lux in the morning might have
some subtle effect on the circadian system. However, the
answers to the questions of whether morning light therapy
will have a beneficial effect on non-seasonal depressive
symptoms in young people, and whether 2 weeks of
morning light will be sufficient to elicit more general posi-
tive effects on the sleep-wake rhythm and on affective
dysregulation, should be answered. Moreover, we expect
insight into possible changes on a physiological level, such
as shifts in DLMO.
After this pilot study has been conducted and specific
effects of bright-light therapy have been observed, a
combination of various chronotherapeutic interventions,
such as light therapy, wake therapy, and additionalsleep-phase advance could be conducted to investigate
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